CYP2D6基因多态性与乳腺癌内分泌治疗  

Progress on the relationship between genetic polymorphism of CYP2D6 and endocrine therapy of breast cancer

作　　者：张萍[1] 顾史洋[1] 覃文新[2] 胡夕春[1] 

机构地区：[1]复旦大学附属肿瘤医院肿瘤内科,复旦大学上海医学院肿瘤学系,上海200032 [2]上海市肿瘤研究所癌基因及相关基因国家重点实验室,上海200032

出　　处：《中国癌症杂志》2009年第12期959-962,共4页China Oncology

摘　　要：CYP2D6是细胞色素P450的一种同工酶,代谢许多临床常用药物。其基因的多态性可以影响他莫昔芬的代谢,从而导致携带不同基因型的乳腺癌患者对他莫昔芬的反应性不同。本文简要综述了CYP2D6基因多态性与他莫昔芬代谢和疗效的关系,药物间的相互作用对他莫昔芬代谢的影响,以及针对不同患者选择个体化内分泌治疗方案。CYP2D6 is one of the cytochrome P450 isozymes which are involved in the metabolism of various drugs with wide use. Polymorphism at the CYP2D6 locus is one of the most widely known causes for pharmacogenetic variability in humans beings. This review focuses on the importance of CYP2D6 polymorphism in the metabolism of tamoxifen, relationships between the genetic polymorphism and prognosis of patients who have underwent endocrine therapy, and evidences indicating that CYP2D6 may be used as a predictive marker for choosing optimal endocrine therapy for patients with breast cancer.

关 键 词：CYP2D6 遗传多态性 他莫昔芬代谢 内分泌治疗 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤] R730.54[医药卫生—临床医学]